These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

67 related items for PubMed ID: 3501795

  • 41. Recombinant interleukin-2 (rIL-2) after autologous bone marrow transplantation (BMT): a pilot study in 19 patients.
    Blaise D, Viens P, Olive D, Stoppa AM, Gabert J, Pourreau CN, Attal M, Gaspard MH, Mannoni P, Jasmin C.
    Eur Cytokine Netw; 1991; 2(2):121-9. PubMed ID: 1813015
    [Abstract] [Full Text] [Related]

  • 42. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor.
    Chang WC, Hsiao MH, Pattengale PK.
    Nat Immun Cell Growth Regul; 1991; 10(2):57-70. PubMed ID: 1881400
    [Abstract] [Full Text] [Related]

  • 43. Generation of cytotoxic cells from murine bone marrow by human recombinant IL 2.
    Koo GC, Manyak CL.
    J Immunol; 1986 Sep 15; 137(6):1751-6. PubMed ID: 2427580
    [Abstract] [Full Text] [Related]

  • 44. Immunomodulatory activity of a novel nucleoside, 7-thia-8-oxoguanosine: I. Activation of natural killer cells in mice.
    Sharma BS, Mhaskar S, Balazs L, Siaw M.
    Immunopharmacol Immunotoxicol; 1992 Sep 15; 14(1-2):1-19. PubMed ID: 1597650
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Cellular source of soluble interleukin 2 receptors in serum of mice after recombinant interleukin 2 administration.
    Wagner DK, Wong HL, Gately MK, Nelson DL.
    Cytokine; 1990 Sep 15; 2(5):337-43. PubMed ID: 1715768
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. In vivo augmentation of the cytotoxicity of spleen lymphocytes against syngeneic B-16 melanoma cells and the suppression of the artificial metastases in C57BL/6 mice by subcutaneous multiple injections of high dose human recombinant interleukin-2 (rIL-2).
    Saijo N, Ozaki A, Nakano H, Sakurai M, Takahashi H, Sasaki Y, Hoshi A.
    J Cancer Res Clin Oncol; 1986 Sep 15; 111(3):182-6. PubMed ID: 3488319
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. "In vivo effects of rIL-2 pretreatment on chemotherapeutically induced in vivo natural cytolytic hyporesponsiveness".
    Lockhart WL, Peacocke N, Ades EW.
    Immunopharmacol Immunotoxicol; 1987 Sep 15; 9(2-3):177-93. PubMed ID: 3501795
    [Abstract] [Full Text] [Related]

  • 57. Systemic administration of recombinant interleukin-6 in mice induces proliferation of lymphoid cells in vivo.
    Puri RK, Leland P.
    Lymphokine Cytokine Res; 1992 Jun 15; 11(3):133-9. PubMed ID: 1391232
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. In vivo effects of recombinant human interleukin 2 on antitumor and antiviral natural immunity in induced or natural murine immunodeficiency states.
    Butler LD, Browne CP, Layman NK, Riedl P, Tang J, Marder P, DeLong D, Manetta J, Bobbitt L, Strnad J.
    Cancer Res; 1988 Nov 01; 48(21):6081-9. PubMed ID: 3048654
    [Abstract] [Full Text] [Related]

  • 60. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
    Hashimoto W, Osaki T, Okamura H, Robbins PD, Kurimoto M, Nagata S, Lotze MT, Tahara H.
    J Immunol; 1999 Jul 15; 163(2):583-9. PubMed ID: 10395644
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.